ValiRx plc

Corporate Governance

Contact Us

Careers

Strategy & Vision

How we work

Board & Management Team

Collaborative Pipeline

Share price information

AIM Rule 26

Reports & presentations

Regulatory News

Updates

Analyst Research

Partnering & Useful Links

Inaphaea Biolabs

Therapeutic Areas

Evaluation Pipeline

Our Pipeline

Home

DM Sans

Following the recent consultation by the London Stock Exchange, new 

 were published in March 2018. One of the key amendments is in respect of AIM Rule 26 (as set out in AIM Notice 50), which now requires AIM companies to state on their website which recognised corporate governance code they apply and how they have applied that code.

The Board of Directors of the Company is committed to developing and applying high standards of corporate governance. The Board of Directors seeks to apply the QCA Code, revised in April 2018 as devised by the Quoted Companies Alliance.

The Quoted Companies Alliance is the independent membership organisation that champions the interests of small to mid-size quoted companies. The QCA Code takes key elements of good governance and applies them in a manner which is workable for the different needs of growing companies.

A revised version of the QCA Code (the “Revised Code”) was published in April 2018, based on the ‘comply or explain’ principle. The QCA Code is constructed around ten broad principles (accompanied by an explanation of what these principles entail, under ‘application’) and a set of disclosures. The Code states what is considered to be appropriate arrangements for growing companies, and asks companies to provide an explanation about how they are meeting the principles through the prescribed disclosures.

The table below sets out the principles, the application recommended by the QCA code. It then sets out how the Company complies with these requirements and departures from code, and provides links to appropriate disclosures. These are based upon the recommended disclosures provided in the QCA code.

These arrangements are also disclosed in the Corporate Governance section of our Annual Report and Accounts which can be viewed here.

These disclosures were last reviewed on 18 November 2024.

The following paragraphs set out ValiRx’s compliance with the ten principles of the QCA Code.

Please click here to access this information.

Valirx is subject to the UK City Code on Takeovers and Mergers.

ValiRx plc prohibits any inducement which may result in a personal gain or advantage to the recipient or any person or body associated with them, and which is intended to influence them to take action which may not be solely in the interests of ValiRx plc or of the person or body employing them or whom they represent.

The information above was last updated on 

ValiRx plc is listed on AIM of the London Stock Exchange under the ticker code (VAL:LON).

ValiRx plc is a member of the Quoted Companies Alliance, the independent membership organisation that champions the interests of small to mid-size quoted companies.

ValiRx plc is a member of One Nucleus and BIA, both the heart of Europe’s largest life science and healthcare cluster.